← Back
Rapport Therapeutics
RAPP · listed on Nasdaq · worth $1.19 billion
$25.05
+3.47% today
Six insiders bought $21.93 million of Rapport Therapeutics stock in the last two weeks. The biggest buyer was James Healy.
Green dot = an insider bought red = sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
32.3M shares
67% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, six insiders bought Rapport Therapeutics stock and five insiders sold. 23 of the 54 sales are marked on the filing as planned in advance; most by company executives. The biggest seller was Abraham Ceesay, Chief Executive Officer.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Director
James Healy
Bought $20M on Oct 28 — 952,380 shares at $21.00, held through a trust or family, 34% of what they now own.
No earlier purchases to measure
Director
Steven M. Paul
Bought $974.3K on Oct 22 — 35,714 shares at $27.28, held through a trust or family, 46% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
Director
John Maraganore
Bought $217.3K on Oct 22 — 8,239 shares at $26.38, held through a trust or family, 100% of what they now own.
No earlier purchases to measure
Planned sales
Form 144 notices filed for Rapport Therapeutics in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
CEO Abraham Ceesay filed to sell 39,470 shares on 6 Oct; sold 6,732 by 21 Oct10b5-1 plan adopted 27 Mar 2026 · Notice on SEC.gov
COO Cheryl Gault filed to sell 10,000 shares on 30 Sep; sold 10,000 by 30 Sep10b5-1 plan adopted 10 Dec 2025 · Notice on SEC.gov
Executive Krishnaswamy Yeleswaram filed to sell 37,000 shares on 25 Aug; sold 50,160 by 25 Aug10b5-1 plan adopted 10 Dec 2025 · Notice on SEC.gov
Big investors
People and funds that reported owning 5% or more of Rapport Therapeutics, newest first.
All reports
Every insider trade and SEC report we hold for Rapport Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Oct 30BoughtJames HealyOct 30 · Traded Oct 28 · Director+27%via a trust or family6,933 @ $21.00$145.6K
Oct 30BoughtJames HealyOct 30 · Traded Oct 28 · Director+25%via a trust or family3,772 @ $21.00$79.2K
Oct 30BoughtJames HealyOct 30 · Traded Oct 28 · Director+36%via a trust or family6,395 @ $21.00$134.3K
Oct 30BoughtJames HealyOct 30 · Traded Oct 28 · Director+34%via a trust or family952,380 @ $21.00$20M
Oct 23SoldAbraham CeesayOct 23 · Traded Oct 21 · Chief Executive Officer · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.2,210 @ $29.16$64.4K
80 more with Pro →Analysts, earnings and news
Analysts' price target
$69.06 average
15 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
2 of 4 quarters above
Q2 '26−$1.19 a share−$0.20
Q1 '26−$0.42 a share+$0.29
Q4 '25−$0.72 a share−$0.05
Q3 '25−$0.71 a share+$0.02